Company intelligence / Profile preview
Brillian Pharma Inc.
Edison, New Jersey, United States of Americabrillianpharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Brillian Pharma has several preclinical candidates including BP-116 for Philadelphia chromosome positive chronic myelogenous leukemia, BP-115 for hypertension, and BP-110 for Attention Deficit Disorder With Hyperactivity
- Therapeutic areas
- PsychiatryOncologyCardiovascular
- Modalities
- Small molecule drugsChemical drugs
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Beyond the preview
Go deeper on Brillian Pharma Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Brillian Pharma Inc..